Compare LOVE & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOVE | PROF |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.3M | 247.5M |
| IPO Year | 2018 | 2017 |
| Metric | LOVE | PROF |
|---|---|---|
| Price | $16.77 | $7.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $25.00 | $12.00 |
| AVG Volume (30 Days) | ★ 242.4K | 71.0K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $697,115,000.00 | $16,098,000.00 |
| Revenue This Year | $4.63 | $92.40 |
| Revenue Next Year | $6.40 | $64.10 |
| P/E Ratio | ★ N/A | $38.58 |
| Revenue Growth | 2.42 | ★ 50.73 |
| 52 Week Low | $10.33 | $3.92 |
| 52 Week High | $20.88 | $8.95 |
| Indicator | LOVE | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 54.80 |
| Support Level | $13.55 | $7.00 |
| Resistance Level | $17.69 | $7.94 |
| Average True Range (ATR) | 1.08 | 0.36 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 57.99 | 49.21 |
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.